Towards novel paradigms for cancer therapy

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

(2010) T Trarbach et al.   BRITISH JOURNAL OF CANCER

Acquired and innate resistance to the cancer-specific apoptosis-inducing Cytokine, mda-7/IL-24: Not insurmountable therapeutic problems

(2010) Devanand Sarkar et al.   CANCER BIOLOGY & THERAPY

Multivalent DR5 Peptides Activate the TRAIL Death Pathway and Exert Tumoricidal Activity

(2010) V. Pavet et al.   CANCER RESEARCH

Thelet-7microRNA reduces tumor growth in mouse models of lung cancer

(2010) Aurora Esquela-Kerscher et al.   CELL CYCLE

Dependence receptors: Mechanisms of an announced death

(2010) Chantal Thibert et al.   CELL CYCLE

Inhibitors of Lactate Dehydrogenase Isoforms and their Therapeutic Potentials

(2010) C. Granchi et al.   CURRENT MEDICINAL CHEMISTRY

Small-molecule pan-IAP antagonists: a patent review

(2010) John A Flygare et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis

(2010) Ling Zhang et al.   NATURE

Dependence receptors: a new paradigm in cell signaling and cancer therapy

(2010) D Goldschneider et al.   ONCOGENE

Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis

(2009) Dominik E. Dorer et al.   ADVANCED DRUG DELIVERY REVIEWS

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

(2009) H. A. Wakelee et al.   ANNALS OF ONCOLOGY

Is TRAIL the holy grail of cancer therapy?

(2009) Thomas Newsom-Davis et al.   APOPTOSIS

Mechanisms of anti-cancer action and pharmacology of clofarabine

(2009) Anna Zhenchuk et al.   BIOCHEMICAL PHARMACOLOGY

miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia

(2009) C. P. Pallasch et al.   BLOOD

Curing APL: Differentiation or Destruction?

(2009) Scott C. Kogan   CANCER CELL

Growth Factor-Antagonized Rexinoid Apoptosis Involves Permissive PPARγ/RXR Heterodimers to Activate the Intrinsic Death Pathway by NO

(2009) Pattabhiraman Shankaranarayanan et al.   CANCER CELL

miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation

(2009) Michela Garofalo et al.   CANCER CELL

Epigenetic Repression of microRNA-129-2 Leads to Overexpression of SOX4 Oncogene in Endometrial Cancer

(2009) Y.-W. Huang et al.   CANCER RESEARCH

Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction

(2009) Ji Luo et al.   CELL

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors

(2009) Astrid Spannhoff et al.   ChemMedChem

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy

(2009) E. Martinelli et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells

(2009) M. Idogawa et al.   CLINICAL CANCER RESEARCH

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

(2009) C. H. Mom et al.   CLINICAL CANCER RESEARCH

Therapy-induced PML/RARA Proteolysis and Acute Promyelocytic Leukemia Cure

(2009) R. Nasr et al.   CLINICAL CANCER RESEARCH

Netrin-1 and its dependence receptors as original targets for cancer therapy

(2009) Patrick Mehlen et al.   CURRENT OPINION IN ONCOLOGY

Inhibition of Endothelial Cell Apoptosis by Netrin-1 during Angiogenesis

(2009) Marie Castets et al.   DEVELOPMENTAL CELL

TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies

(2009) Peter A. Holoch et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Proteins selectively killing tumor cells

(2009) Mathieu H.M. Noteborn   EUROPEAN JOURNAL OF PHARMACOLOGY

Acute myelogenous leukemia

(2009) Joshua L. Shipley et al.   EXPERIMENTAL HEMATOLOGY

PTD4-apoptin protein therapy inhibits tumor growthin vivo

(2009) Jun Sun et al.   INTERNATIONAL JOURNAL OF CANCER

Oncolytic virus therapy for prostate cancer

(2009) Hiroshi Fukuhara et al.   INTERNATIONAL JOURNAL OF UROLOGY

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

The Adenovirus E4orf4 Protein Induces G2/M Arrest and Cell Death by Blocking Protein Phosphatase 2A Activity Regulated by the B55 Subunit

(2009) S. Li et al.   JOURNAL OF VIROLOGY

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

(2009) Sohrab P. Shah et al.   NATURE

The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs

(2009) Helena Persson et al.   NATURE CELL BIOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Adverse effects of anticancer agents that target the VEGF pathway

(2009) Helen X. Chen et al.   Nature Reviews Clinical Oncology

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules

(2009) Axel Grothey et al.   Nature Reviews Clinical Oncology

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

(2009) Pasi A. Jänne et al.   NATURE REVIEWS DRUG DISCOVERY

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

(2009) Bin-Bing S. Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Programmed Cell Death Pathways and Current Antitumor Targets

(2009) Mei Lan Tan et al.   PHARMACEUTICAL RESEARCH

Changes in Proteasome Structure and Function Caused by HAMLET in Tumor Cells

(2009) Lotta Gustafsson et al.   PLoS One

Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach

(2009) Brian T. Kawasaki et al.   PROSTATE

DNA Polymerases as Therapeutic Targets†

(2008) Anthony J. Berdis   BIOCHEMISTRY

Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data

(2008) D. C. Hassane et al.   BLOOD

Medulloblastoma Can Be Initiated by Deletion of Patched in Lineage-Restricted Progenitors or Stem Cells

(2008) Zeng-Jie Yang et al.   CANCER CELL

Methylation Mediated Silencing of MicroRNA-1 Gene and Its Role in Hepatocellular Carcinogenesis

(2008) J. Datta et al.   CANCER RESEARCH

TRAIL induces proliferation of human glioma cells by c-FLIPL-mediated activation of ERK1/2

(2008) U. Vilimanovich et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

(2008) G. Lurje et al.   CLINICAL CANCER RESEARCH

Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24

(2008) Suhendan Ekmekcioglu et al.   CYTOKINE

TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them

(2008) A THORBURN et al.   DRUG RESISTANCE UPDATES

Ad-MDA-7; INGN 241: a review of preclinical and clinical experience

(2008) Robert Eager et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Gene therapy progress and prospects cancer: oncolytic viruses

(2008) T-C Liu et al.   GENE THERAPY

HAMLET (human α-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death

(2008) Sonja Aits et al.   INTERNATIONAL JOURNAL OF CANCER

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitor of apoptosis proteins in hematological malignancies

(2008) S Fulda   LEUKEMIA

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

(2008) F. Anthony Greco et al.   LUNG CANCER

TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8

(2008) Larisa L. Belyanskaya et al.   LUNG CANCER

Identification of cells initiating human melanomas

(2008) Tobias Schatton et al.   NATURE

Efficient tumour formation by single human melanoma cells

(2008) Elsa Quintana et al.   NATURE

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

(2008) Rihab Nasr et al.   NATURE MEDICINE

BCL-2 family antagonists for cancer therapy

(2008) Guillaume Lessene et al.   NATURE REVIEWS DRUG DISCOVERY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE

The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells

(2008) S Li et al.   ONCOGENE

Apoptin: Therapeutic Potential of an Early Sensor of Carcinogenic Transformation

(2007) Claude Backendorf et al.   Annual Review of Pharmacology and Toxicology

Non-coding RNAs, epigenetics and complexity

(2007) Fabrício F. Costa   GENE